Thorsten P. Degenhardt
Geschäftsführer bei Mycovia Pharmaceuticals, Inc.
Aktive Positionen von Thorsten P. Degenhardt
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Mycovia Pharmaceuticals, Inc.
 Mycovia Pharmaceuticals, Inc. BiotechnologyHealth Technology Mycovia Pharmaceuticals, Inc. develops novel drugs in areas of unmet medical need, with an initial focus in women?s health. Its product candidate, VT-1161, engages in developed as a treatment for recurrent vulvovaginal candidiasis. The company was founded in 2018 and is headquartered in Durham, NC. | Geschäftsführer | - | - |
Karriereverlauf von Thorsten P. Degenhardt
Ehemalige bekannte Positionen von Thorsten P. Degenhardt
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
BioStratum, Inc.
 BioStratum, Inc. Pharmaceuticals: MajorHealth Technology BioStratum, Inc. develops and distributes pharmaceutical products. Its products are used for treatment of diabetes and diabetic complications. The firm also develops anti-tumor, cancer, diabetic kidney disease and diabetic eye disease drugs. The company was founded by Karl Tryggvason and J. Wesley Fox in 1994 and is headquartered in Durham, NC. | Corporate Officer/Principal | - | - |
| University of South Carolina | Corporate Officer/Principal | - | - |
Cempra Pharmaceuticals, Inc.
 Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | 28.04.2009 | - |
Ausbildung von Thorsten P. Degenhardt
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| Technische Universität Darmstadt | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Deutschland | 3 |
Operativ
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Cempra Pharmaceuticals, Inc.
Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Health Technology |
BioStratum, Inc.
BioStratum, Inc. Pharmaceuticals: MajorHealth Technology BioStratum, Inc. develops and distributes pharmaceutical products. Its products are used for treatment of diabetes and diabetic complications. The firm also develops anti-tumor, cancer, diabetic kidney disease and diabetic eye disease drugs. The company was founded by Karl Tryggvason and J. Wesley Fox in 1994 and is headquartered in Durham, NC. | Health Technology |
Mycovia Pharmaceuticals, Inc.
Mycovia Pharmaceuticals, Inc. BiotechnologyHealth Technology Mycovia Pharmaceuticals, Inc. develops novel drugs in areas of unmet medical need, with an initial focus in women?s health. Its product candidate, VT-1161, engages in developed as a treatment for recurrent vulvovaginal candidiasis. The company was founded in 2018 and is headquartered in Durham, NC. | Health Technology |
- Börse
- Insiders
- Thorsten P. Degenhardt
- Erfahrung
